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Aarhus University Hospital and 3) Department of Clinical Medicine, Aalborg University, Aalborg, DenmarkAbstractIn patients hospitalized with severe infection, premature discharge may lead to increased risk of readmission and death. We conducted this
population-based cohort study to examine trends in length of stay (LOS) and 30-day mortality and hospital readmission rates after
bacteraemia from 1994 through 2013. We used Cox regression to compute hazard ratios (HRs) for 30-day mortality and 30-day
postdischarge readmission rates by calendar period and quintiles of LOS, adjusting for age, sex and comorbidity. Among 7618 patients
hospitalized with community-acquired bacteraemia during the study period, median LOS decreased from 12 days (quartiles 7–21 days) in
1994–1998 to 9 days (quartiles 6–16 days) in 2009–2013 (25% relative reduction). The 30-day mortality fell from 16.7% to 15.0%,
yielding an adjusted 30-day HR of 0.80 (95% conﬁdence interval (CI) 0.68–0.95). Almost one ﬁfth (19.4%) of patients discharged alive
were readmitted within 30 days. Concurrently, the adjusted HR of readmission tended to increase (adjusted HR 1.09, 95% CI 0.93–1.28)
in 2009–2013 compared with 1994–1998. Compared with the middle quintile of LOS (9–12 days), the risk of readmission was slightly
higher for patients discharged within 5 days (adjusted HR 1.12, 95% CI 0.92–1.37), especially for readmission due to infection (adjusted
HR 1.38, 95% CI 1.03–1.85). Readmission risk was lowest for 6 to 8 days LOS (adjusted HR 0.80, 95% CI 0.67–0.95) and highest for
LOS 23 days (adjusted HR 1.30, 95% CI 1.11–1.53). The declining LOS after community-acquired bacteraemia between 1994 and 2013
was not accompanied by increased 30-day mortality but by slightly increased readmission rates.
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E-mail: mso@clin.au.dkIntroductionHospitalizations for bacteraemia have risen over the past
decade in the United States and Europe [1,2]. In 2008, bac-
teraemia was responsible for more than 700 000 hospitaliza-
tions in the United States, costing approximately $14.6 billion,
and inﬂation-adjusted costs for treating bacteraemia patients
increased by 11.9% annually during the last decade [3]. BecauseClinical Microbiology and Infection © 2015 European Society of Clength of stay (LOS) is the primary determinant of hospital costs
[4,5], reducing LOS for bacteraemic patients may have sub-
stantial economic implications. On the other hand, excessive
reduction in LOS may lead to premature discharges and
potentially more deaths after discharge and increases in read-
mission rates.
For patients hospitalized with pneumonia, several studies
have documented substantial decreases in LOS over the last
decades [6–9]. In many studies, the reduction in LOS was not
accompanied by higher mortality or more readmissions [6–8].
In others, more patients were discharged in an unstable con-
dition, and subsequent mortality and readmission rates were
increased in these patients [10,11]. To our knowledge, no
studies have investigated temporal changes in LOS, mortalityClin Microbiol Infect 2015; 21: 789.e1–789.e7
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teraemia. We therefore conducted this population-based
cohort study focussing on trends in LOS after community-
acquired bacteraemia over a 20-year period and whether
declining LOS was associated with increased risk of 30-day
mortality and readmission.MethodsSetting
We conducted this cohort study in North Denmark Region, with
approximately 500 000 inhabitants. All residents are provided
with free tax-supported health care. A unique personal identiﬁer
assigned to each Danish citizen at birth allowed for accurate
individual-level linkage of bacteraemia patients to a number of
population-based registries. The Danish Data Protection Agency
approved the study (Record No. 2006-41-7413).
Data on bacteraemia
We included patients (15 years) hospitalized with a ﬁrst
episode of community-acquired bacteraemia recorded in the
North Denmark Bacteraemia Research Database between
1994 and 2013. This microbiologic database, which has been
fully described elsewhere [12], contains detailed information on
all episodes of bacteraemia in the region since 1981.
We deﬁned community-acquired bacteraemia as an infection
that was present or incubating at hospital admission evidenced
by one or more blood cultures with growth of bacteria or fungi
given clinical signiﬁcance by a medically trained clinical micro-
biologist and the attending physician. We regarded coagulase-
negative staphylococci, Corynebacterium spp., Bacillus spp. and
Propionibacterium acnes as contaminants unless they were iso-
lated from two or more separate blood culture sets [12]. Pa-
tients with hospital contact within 30 days up till the
bacteraemia episode or regular contact to the hospital (e.g. for
hemodialysis or chemotherapy) were excluded [12]. Empirical
antibiotic treatment, deﬁned as the treatment given before the
ﬁrst notiﬁcation of a positive blood culture, was regarded as
appropriate if administered intravenously (exception for ﬂuo-
roquinolones and metronidazole, for which all routes of
administration were regarded as appropriate) and if the blood
isolates were susceptible in vitro to one or more of the antibi-
otics given. The probable focus of infection was assessed on the
basis of all available clinical, paraclinical and microbiologic
ﬁndings and imaging results.
Data on covariates
Comorbidity was classiﬁed according to the Charlson comor-
bidity index [13]. We calculated these scores on the basis ofClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectdiagnoses recorded in the Danish National Registry of Patients
(DNRP) within 10 years preceding the date of bacteraemia. We
deﬁned three comorbidity levels: low (score of 0), medium
(score of 1–2) and high (score 3). We also obtained data on
alcoholism-related disorders not included in the Charlson index
(ICD-8 codes 291, 303, 979, 980, 577.10; ICD-10 codes F10,
K86.0, Z72.1, R78.0, T51, K29.2, G62.1, G72.1, G31.2, I42.6).
Through population-based prescription databases [14], we
retrieved information on use of immunosuppressants within the
year before the index admission (ATC-codes L01, L04, H02
AB), and use of systemic antibiotics within 90 days before
admission (ATC-code J01). As a marker of social status, we
obtained information from the Civil Registration System on
marital status (married, never married, divorced or widowed)
at date of diagnosis. As a measure of bacteraemia severity, we
obtained information on intensive care unit (ICU) admissions
through the DNRP and information on laboratory ﬁndings
(leucocyte counts, C-reactive protein, creatinine, glucose, urea
nitrogen) on the day of admission (or the day before, if un-
available) through a laboratory database recording all specimens
sent by hospitals and practitioners [15]. Laboratory data were
available from 1997 through 2011.
Outcome measures
Outcome measures included LOS (deﬁned as the difference
between hospital admission and discharge dates), 30-day mor-
tality and 30-day postdischarge readmission (deﬁned as a hos-
pital inpatient readmission from any cause within 30 days after
the date of discharge). If more than one readmission occurred
in the 30-day period, we considered only the ﬁrst readmission.
Complete information on LOS and readmissions was obtained
from the DNRP, and up-to-date information on mortality was
obtained from the Civil Registration System.Statistical analysis
Descriptive statistics included frequency tables and median and
interquartile range (IQR) over four 5-year calendar periods. To
further assess temporal changes in LOS, we stratiﬁed by age
group (15–64, 65–79 and 80 years) and comorbidity. We
used Cox regression analysis to examine changes in hazard
ratios (HRs) with 95% conﬁdence intervals (CIs) for 30-day
mortality and 30-day readmission by calendar period, adjust-
ing for age, sex and comorbidity. Each outcome was analysed
separately, and we considered death a competing risk for
readmission [16]. Further, we conducted analyses restricted to
patients with acute readmissions and readmissions with in-
fections. Finally, we examined the association between LOS and
risk of 30-day postdischarge readmission using Cox regression,
adjusting for age, sex and comorbidity. For this analysis, we
categorized LOS as quintiles.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 789.e1–789.e7
CMI Søgaard et al. Length of stay and outcome of bacteraemia 789.e3ResultsTrends in patient characteristics
There were 7618 ﬁrst-time episodes of community-acquired
bacteraemia from 1994 through 2013. Although the median
age remained almost unchanged, the proportion of patients
aged 80 years increased from 30.4% to 34.3% (Table 1).
Preadmission comorbidity increased over time. Especially the
proportion of patients with diabetes with or without end-stage
organ damage (12.9% to 22.8%), chronic pulmonary disease
(11.9% to 17.2%), cerebrovascular disease (9.1% to 15.8%) and
solid cancer (13.1% to 19.6%) increased, whereas congestive
heart failure (11.7% to 8.7%) decreased. The proportion of
patients who received appropriate empirical antibiotic treat-
ment increased markedly, from 60.5% during 1994–1998 to
74.6% during 2009–2013. Nonetheless, one ﬁfth of patients still
received inappropriate empirical antibiotic treatment at the
time of ﬁrst notiﬁcation in 2009–2013. The proportion of ICU
admissions decreased slightly from 6.0% in 1994–1998 to 4.4%
in 2009–2013. However, patients diagnosed in 2009–2013 had
similar levels of biochemical markers of sepsis on the date of
blood culture as patients diagnosed in 1994–1998 (Table 1).
Trends in LOS
The median LOS decreased from 12 days (IQR 7–21 days) in
1994–1998 to 9 days (IQR 6–16 days) in 2009–2013 (25%
relative reduction). Fig. 1 shows the trends by quintiles of LOS
by calendar period. In 1994–1998, 15.5% of patients were
hospitalized for 5 days compared with 19.2% in 2009–2013.
Extremely long LOS (23 days) decreased from 23.9% in
1994–1998 to 17.8% in 2009–2013. Stratifying by age revealed
the largest reductions in LOS among patients aged 15 to 64
(20% reduction) and 65 to 79 years (23% reduction) compared
with patients aged 80 years (17% reduction). Similarly, median
LOS decreased by 25% and 10% in patients with low and me-
dium levels of comorbidity, respectively, but remained stable in
patients with high comorbidity.
Trends in 30-day mortality and readmissions
The overall 30-day mortality was 15.8% and was 16.7% in pa-
tients diagnosed in 1994–1998, 16.5% in 1999–2003, 15.3% in
2004–2008 and 15.0% in 2009–2013. Only 11.6% of deaths
within 30 days occurred after hospital discharge. This propor-
tion was 10.3% (29 patients) in 1994–1998 and 11.7% (36 pa-
tients) in 2009–2013. Compared with patients diagnosed in
1994–1998, the adjusted HR for 30-day mortality was 0.95
(95% CI 0.81–1.11) in 1999–2003, 0.88 (95% CI 0.75–1.03) in
2004–2008 and 0.80 (95% CI 0.68–0.95) in 2009–2013.
Of the 7618 patients, 1169 (15.4%) died in hospital, while
6449 (84.7%) were discharged alive. Of these, 1254 (19.4%)Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inwere readmitted to hospital within 30 days of discharge, of which
998 (79.6%) were acute readmissions and 556 (44.3%) had a
diagnosis of infection (439 (35.0%) with primary-listed infection).
Table 2 displays crude and adjusted HRs for readmissions by
calendar period. The 30-day readmissions increased from 18.4%
in 1994–1998 to 21.2% in 2009–2013. After adjustment for
potential confounders, the HRs for readmission in 1999–2003
and 2004–2008 were fairly equal, at 1.00 (95% CI 0.85–1.19)
and 1.01 (95% CI 0.86–1.19), respectively, compared with that in
1994–1998, but increased in 2009–2013 (adjusted HR 1.09, 95%
CI 0.93–1.28), Similar trends were observed in analyses
restricted to patients with urgent readmissions (Table 2).LOS and risk of 30-day readmission
Among patients discharged alive, the prevalence of 30-day
postdischarge readmission was 19.3% for patients with LOS
5 days, 15.2% for patients with LOS of 6 to 8 days, 18.8% for
patients with LOS of 9 to 12 days, 21.3% for patients with LOS of
13 to 22 days and 23.2% for patients with LOS 23 days
(Supplementary Table S1). Fig. 2 shows adjusted HRs by quintiles
of LOS. Compared with the middle quintile of hospital stay
(9–12 days), we found a J-shaped curve pattern—that is, the HR
for readmission tended to be higher for patients with stays of5
days (adjusted HR 1.12, 95% 0.92–1.37), lowest for patients with
6 to 8 days’ stay (adjusted HR 0.80, 95% CI 0.67–0.95) and then
higher for patients hospitalized for longer than 12 days, especially
for those hospitalized 23 days (adjusted HR 1.30, 95% CI
1.11–1.53) (Fig. 2). Among the 556 patients (44.3%) readmitted
for infection, we noted a high risk of readmission among those
with LOS 5 days (adjusted HR 1.38, 95% CI 1.03–1.85).DiscussionThis study began with a concern that efﬁciency improvement
and early discharge policies had resulted in substantial de-
clines in LOS among patients with community-acquired bac-
teraemia, possibly at the expense of more readmissions and
deaths after discharge. The analysis of 20 years of bacter-
aemias did not support this concern. Although the median
LOS declined by 3 days, there was only a slight increase in
readmission risk in the most recent years and a decrease in
mortality. However, we found a J-shaped curve pattern with a
slightly higher risk of readmission for patients discharged
within 5 days, in particular for readmissions with infection
diagnosis, compared with the middle quintile of LOS (9–12
days). For patients with long hospital stays, readmission risk
was also increased, probably as a result of increased severity
of bacteraemia or underlying conditions during the index
hospitalization.fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 789.e1–789.e7
TABLE 1. Clinical and microbiologic characteristics of 7618 patients with ﬁrst-time community-acquired bacteraemia in Northern
Denmark, 1994–2013
Characteristic
n (%) of patients for study period:
Prevalence rate ratio (95% CI),
2009–2013 vs. 1994–19981994–1998 1999–2003 2004–2008 2009–2013
Patients, total 1679 1877 2019 2043 1.22 (1.15–1.29)
Specialty
Internal medicine 1262 (75.2) 1405 (74.9) 1562 (77.4) 1600 (78.3) 1.04 (1.00–1.07)
Surgery 313 (18.6) 382 (20.4) 402 (19.9) 353 (17.3) 0.93 (0.81–1.06)
Intensive care 101 (6.0) 89 (4.7) 44 (2.2) 90 (4.4) 0.73 (0.55–0.97)
Data missing 3 (0.2) 1 (0.1) 11 (0.5) 0 —
Age group, years
15–64 527 (31.4) 586 (31.2) 684 (33.9) 618 (30.3) 0.91 (0.82–1.00)
65–79 642 (38.2) 709 (37.8) 699 (34.6) 725 (35.5) 0.93 (0.85–1.01)
80 510 (30.4) 582 (31.0) 636 (31.5) 700 (34.3) 1.13 (1.03–1.24)
Median age (IQR) 73.4 (61.0–81.5) 74.4 (60.9–82.1) 73.4 (59.8–82.1) 74.0 (62.4–83.0) —
Sex
Female 851 (50.7) 972 (51.8) 1047 (51.9) 1000 (49.0) 0.97 (0.91–1.03)
Male 828 (49.3) 905 (48.2) 972 (48.1) 1043 (51.5) 1.04 (0.97–1.10)
Marital status
Married 780 (46.5) 862 (45.9) 948 (47.0) 928 (45.4) 0.98 (0.91–1.05)
Never married 220 (13.1) 253 (13.5) 275 (13.6) 281 (13.8) 1.05 (0.89–1.24)
Divorced or widowed 679 (40.4) 762 (40.6) 796 (39.4) 834 (40.8) 1.00 (0.93–1.09)
Comorbidities included in the Charlson index
Previous myocardial infarction 114 (6.8) 148 (7.9) 175 (8.7) 186 (9.1) 1.34 (1.07–1.68)
Congestive heart failure 196 (11.7) 227 (12.1) 200 (9.9) 177 (8.7) 0.74 (0.61–0.90)
Peripheral vascular disease 108 (6.4) 160 (8.5) 158 (7.8) 167 (8.2) 1.27 (1.00–1.60)
Cerebrovascular disease 153 (9.1) 248 (13.2) 267 (13.2) 322 (15.8) 1.73 (1.44–2.07)
Dementia 26 (1.6) 33 (1.8) 43 (2.1) 65 (3.2) 2.05 (1.31–3.22)
Hemiplegia 9 (0.5) 12 (0.6) 12 (0.6) 19 (0.9) 1.73 (0.79–3.82)
Chronic pulmonary disease 200 (11.9) 257 (13.7) 315 (15.6) 351 (17.2) 1.44 (1.23–1.69)
Connective tissue disease 76 (4.5) 115 (6.1) 95 (4.7) 123 (6.0) 1.33 (1.01–1.76)
Peptic ulcer disease 139 (8.3) 187 (10.0) 202 (10.0) 186 (9.1) 1.10 (0.89–1.36)
Mild liver disease 35 (2.1) 46 (2.5) 60 (3.0) 51 (2.5) 1.20 (0.78–1.86)
Moderate to severe liver disease 10 (0.6) 22 (1.2) 26 (1.3) 24 (1.2) 1.97 (0.95–4.11)
Diabetes without end-stage organ damage 168 (10.0) 187 (10.0) 235 (11.6) 281 (13.8) 1.37 (1.15–1.65)
Diabetes with end-stage organ damage 49 (2.9) 99 (5.3) 136 (6.7) 184 (9.0) 3.09 (2.27–4.20)
Moderate to severe renal disease 48 (2.9) 61 (3.3) 81 (4.0) 118 (5.8) 2.02 (1.45–2.08)
Solid cancer 220 (13.1) 264 (14.1) 309 (15.3) 401 (19.6) 1.50 (1.29–1.74)
Metastatic solid cancer 34 (2.0) 36 (1.9) 46 (2.3) 61 (3.0) 1.47 (0.97–2.23)
Leukemia 16 (1.0) 12 (0.6) 14 (0.7) 19 (0.9) 0.98 (0.50–1.89)
Lymphoma 23 (1.4) 24 (1.3) 25 (1.2) 26 (1.3) 0.93 (0.53–1.62)
AIDS 0 2 (0.1) 2 (0.1) 2 (0.1) —
Comorbidity index
Low (0) 750 (44.7) 736 (39.2) 806 (39.9) 732 (35.8) 0.80 (0.74–0.87)
Medium (1–2) 639 (38.1) 757 (40.3) 745 (36.9) 737 (36.1) 0.95 (0.87–1.03)
High (>2) 290 (17.3) 384 (20.5) 468 (23.2) 574 (28.1) 1.63 (1.43–1.84)
Alcoholism-related conditions 93 (5.7) 89 (4.7) 147 (7.3) 143 (7.0) 1.26 (0.98–1.63)
Preadmission medication
Immunosuppressive drugs 278 (16.6) 292 (15.6) 301 (14.9) 330 (16.2) 0.98 (0.84–1.13)
Systemic antibiotic therapy within 3 months prior to admission 512 (30.5) 641 (34.2) 707 (35.0) 734 (35.9) 1.18 (1.07–1.29)
Isolated pathogen
Staphylococcus aureus 135 (8.0) 144 (7.7) 157 (7.8) 166 (8.1) 1.01 (0.81–1.26)
Haemolytic streptococci 82 (4.9) 91 (4.9) 101 (5.0) 132 (6.5) 1.32 (1.01–1.73)
Pneumococci 350 (20.9) 317 (16.9) 349 (17.3) 281 (13.8) 0.66 (0.57–0.76)
Other Gram-positive pathogens 127 (7.6) 145 (7.7) 168 (8.3) 174 (8.5) 1.13 (0.90–1.40)
Escherichia coli 558 (33.2) 708 (37.7) 730 (36.2) 749 (36.7) 1.01 (1.00–1.21)
Other Enterobacteriaceae 181 (10.8) 208 (11.1) 217 (10.8) 250 (12.2) 1.14 (0.95–1.36)
Other Gram-negative pathogens 96 (5.7) 104 (5.5) 133 (6.6) 134 (6.6) 1.15 (0.89–1.48)
Polymicrobial or fungemia 150 (8.9) 160 (8.5) 164 (8.1) 157 (7.7) 0.86 (0.69–1.07)
Focus of infection
Urinary tract 502 (29.9) 683 (35.9) 676 (33.5) 635 (31.1) 1.04 (0.94–1.15)
Respiratory tract 337 (20.1) 283 (15.1) 338 (16.7) 287 (14.1) 0.70 (0.61–0.81)
Abdominala 331 (19.7) 284 (15.1) 297 (14.7) 275 (13.5) 0.68 (0.59–0.79)
Miscellaneousb 238 (14.2) 276 (14.7) 258 (12.8) 213 (10.4) 0.69 (0.58–0.82)
Unknown 271 (16.1) 361 (19.2) 450 (22.3) 633 (31.0) 1.92 (1.69–2.18)
Empirical antibiotic treatment
Appropriate 1015 (60.5) 1171 (62.4) 1415 (70.1) 1515 (74.6) 1.23 (1.17–1.28)
Inappropriate 516 (30.7) 516 (27.5) 433 (21.5) 384 (18.8) 0.61 (0.55–0.69)
Treatment ceasedc 107 (6.4) 139 (7.4) 144 (7.1) 141 (6.9) 1.08 (0.85–1.38)
No information 41 (2.4) 51 (2.7) 27 (1.3) 3 (0.2) —
Laboratory ﬁndings, median (IQR)d
Leucocyte count, 109/L (ref: 4.5–11.0) 13.7 (9.8–9.9) 13.9 (9.9–19.2) 13.9 (9.9–19.0) 13.8 (9.4–19.2) —
C-reactive protein, mg/L (ref: <10) 151 (63–245) 166 (71–269) 164 (67–271) 140 (59–242) —
Creatinine, μmol/L (ref: female 55–115; male 60–125) 108 (84–146) 107 (84–152) 103 (78–155) 96 (73–142) —
Glucose, mmol/L (ref: 3.1–7.8) 6.4 (5.4–7.9) 6.5 (5.5–8.0) 6.5 (5.5–8.3) 7.0 (5.9–8.5) —
Urea nitrogen, mmol/L (ref: 3.0–7.5) 8.1 (5.4–13.8) 8.7 (5.7–13.8) 8.7 (5.9–14.1) 9.1 (6.1–14.4) —
CI, conﬁdence interval; IQR, interquartile range.
aGastrointestinal and hepatobiliary tracts.
bCentral nervous system, muscle, skin, joints and bones, genital system and intravascular devices.
cTreatment was completed or patients had either died or were in terminal stages of disease.
dLaboratory ﬁndings on the date of blood culture (or the day before, if unavailable). For 1994–1998, results are available for approximately 50% of patients, except urea nitrogen
(available for 25% of patients). For 1999–2011, results are available for >95% of patients, except glucose and urea nitrogen (available for 60% of patients). Laboratory data for 2012
and 2013 were not available.
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FIG. 1. Quintiles of hospital LOS by study
period.
TABLE 2. Hazard ratios for readmission within 30-days
postdischarge among 6449 patients discharged alive after
hospitalization with community-acquired bacteraemia
Study period








1994–1998 257 (18.4) 1.00 (reference) 1.00 (reference)
1999–2003 299 (19.0) 1.02 (0.87–1.21) 1.00 (0.85–1.19)
2007–2008 328 (19.0) 1.04 (0.88–1.22) 1.01 (0.86–1.19)
2009–2013 370 (21.2) 1.17 (1.00–1.37) 1.09 (0.93–1.28)
Acute readmissions
1994–1998 200 (14.3) 1.00 (reference) 1.00 (reference)
1999–2003 238 (15.1) 1.05 (0.87–1.27) 1.02 (0.85–1.23)
2007–2008 258 (14.9) 1.05 (0.87–1.26) 1.01 (0.84–1.22)
2009–2013 302 (17.3) 1.22 (1.02–1.46) 1.13 (0.95–1.36)
Readmissions with infections
1994–1998 102 (7.3) 1.00 (reference) 1.00 (reference)
1999–2003 128 (8.1) 1.11 (0.86–1.44) 1.09 (0.84–1.41)
2007–2008 151 (8.7) 1.20 (0.94–1.55) 1.18 (0.91–1.51)
2009–2013 175 (10.0) 1.39 (1.09–1.78) 1.31 (1.03–1.68)
HR, hazard ratio; CI, conﬁdence interval.
aAdjusted for sex, age group and level of comorbidity considering death as
competing risk.
CMI Søgaard et al. Length of stay and outcome of bacteraemia 789.e5Although our study may be the ﬁrst to examine trends in
readmission in patients with bacteraemia, several studies have
addressed trends for various other diseases, including pneu-
monia [6–9]. We particularly noted an increased risk of read-
mission with infection among patients discharged within 5 days.
Very short LOS could impede effective antibiotic treatment. In
a Korean cohort study of 483 patients with Staphylococcus
aureus bacteraemia, antibiotic treatment duration of <14 days
was associated with a higher frequency of treatment failure
(26.3% vs. 21.9%) and relapse (7.9% vs 0%) compared with
patients treated 14 days [17]. However, there are few data on
minimally acceptable durations of treatment for bacteraemiaClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and In[18]. LOS predominantly declined for patients aged 65 to 79
years and those with low or medium levels of comorbidity.
Smaller decreases were noted among patients aged 80 years
and those with a high level of comorbidity. In line with this, a
survey among physicians responsible for the discharge of pa-
tients with community-acquired pneumonia have shown that
the most common reason contributing to extended LOS was
treatment of comorbid conditions [19].
Several factors may have contributed to the declining LOS
over time. During the study period, the number of hospitals
declined from seven to four, and acute admission units were
introduced in 2002. From 2007 onwards, sepsis bundles were
implemented. Concurrently, the appropriateness of empirical
antibiotic treatment increased markedly. Appropriate antibiotic
treatment has been associated with earlier discharge [20,21],
though this is at odds with other studies [22]. Increasing
availability of advanced diagnostic tools, including computed X-
ray tomography and magnetic resonance imaging, have likely
contributed to increased and earlier recognition and eradica-
tion of the focus of infection. Increased ascertainment over
time may also have resulted in identiﬁcation of milder cases of
bacteraemia with better prognosis and shorter LOS. We lack
data on disease severity, but the proportion of patients
admitted to the ICU decreased slightly over time despite a
moderate increase in the numbers of ICU beds. Nonetheless,
leucocyte count, levels of C-reactive protein and plasma
creatinine at admission were virtually unchanged over time, and
the proportion of patients aged 80 years increased, as did the
proportion of patients with comorbidity. Therefore, we ﬁnd it
unlikely that changing thresholds for admitting patients with
bacteraemia should have inﬂuenced LOS to a major extent.fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 789.e1–789.e7
FIG. 2. Adjusted cause-speciﬁc haz-
ard ratio of readmission 30 days after
hospital discharge by LOS.
789.e6 Clinical Microbiology and Infection, Volume 21 Number 8, August 2015 CMIIt is important to note the severe burden of illness carried
by community-acquired bacteraemia; 15.4% died during hos-
pitalization, and of those who survived the initial hospitaliza-
tion, almost one ﬁfth (19.4%) were readmitted in the next 30
days. The rate of readmissions is consistent with the rate in
Medicare beneﬁciaries in 2003–2004 (19.6%) reported by
Jencks et al. [23]. The high rate of readmissions is concerning
because readmissions are costly, and from the patient’s
perspective, acute readmission is an adverse event [24]. We
only examined all-cause and infection-related readmission, but
Dharmarajan et al. [25] showed that 30-day readmission in
older patients initially hospitalized with heart failure, acute
myocardial infarction or pneumonia were associated with a
broad range of diagnoses that differed from the speciﬁc
diagnosis responsible for the index admission. This could
reﬂect a generalized vulnerability to illness among recently
discharged patients. Readmission is commonly used as a
quality indicator, though its usefulness is widely debated [26].
A number of studies have argued that many readmissions may
be preventable [23,27,28], while a meta-analysis found that
fewer than one in four readmissions were avoidable [29]. The
high rate observed in our study might result in part from poor
discharge planning and inadequate home care services since
80% of the readmissions were acute. On the other hand,
patients who die during the index admission are not at risk of
readmission. Thus, higher rates could also be a consequence
of more successful care rather than a lack of quality and
continuity [27]. For example, Gorodeski et al. [24] showed
that higher readmission rates after index admissions for heart
failure were associated with lower 30-day mortality. Hence,
the better we get at treating older patients and patients withClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectmultimorbidity, the more patients will be eligible for
readmission.
As a result of universal health care coverage in Denmark, we
were able to include all episodes of community-acquired bac-
teraemia with complete follow-up for mortality and read-
mission. Nonetheless, use of administrative data precluded the
evaluation of the extent of clinical recovery at the time of
discharge as well as the consideration of the quality of care. We
lacked data on postdischarge outpatient care and transfer to
nursing facilities. Also, we did not consider other important
outcomes such as changes in functional status, quality of life and
return to work or normal activity over time [30].
In conclusion, patients hospitalized with community-
acquired bacteraemia experienced a decline in LOS over time
which was accompanied by a slightly increased risk of read-
mission in the most recent years when controlling for changes
in patient age and comorbidity. Our ﬁndings revealed a J-shaped
pattern with relatively higher risks of readmission for patients
with very short stays (5 days) or very long stays (23 days).Transparency declarationAll authors report no conﬂicts of interest relevant to this
article.Appendix A. Supplementary dataSupplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.cmi.2015.05.018.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 789.e1–789.e7
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